SCYNEXIS, Inc., a medicinal chemistry-focused drug discovery and development company, has sold its wholly-owned subsidiary in the United Kingdom, SCYNEXIS Europe Limited, to its U.K. management. The new company will operate under the name Selcia Limited.
